Pharmaceutical Executive
The European Medicines Evaluation Agency (EMEA) has promised to get tough with pharma companies if they fail to follow its rules for reporting product side effects. It may resort to naming and shaming those that do not comply and could even prosecute offenders.
The European Medicines Evaluation Agency (EMEA) has promised to get tough with pharma companies if they fail to follow its rules for reporting product side effects. It may resort to naming and shaming those that do not comply and could even prosecute offenders.
As several high-profile withdrawals have shown, no matter how carefully companies carry out and analyze Phase III trials, those studies are not extensive enough to pick up all potential serious adverse reactions that more widespread use may reveal. That came into sharp focus recently with Bayer's withdrawal of Baycol (cerivastatin) after several deaths were linked to use of the product. More recently, Abbott's anti-obesity drug Meridia (sibutramine) was removed from the market in Italy following a number of adverse events.
During his first year in office, EMEA head Thomas Lonngren has emphasized the importance of pharmacovigilance. As a result, the agency recently issued a position paper on compliance with pharmacovigilance regulatory obligations, following extensive consultation with all interested parties, from national regulatory agencies to pharma companies. Key points include the need for companies to:
The agency has threatened to get tough with companies it believes are not taking their responsibilities as seriously as they should.
EMEA also introduced an electronic reporting system in December 2001 to facilitate quicker and easier reporting and monitoring of adverse effects. Now pharma companies and national authorities are undertaking the difficult process of entering all relevant data on the system.
An EMEA spokesman says it will be a couple of years yet before the system is fully operational. But, ultimately, it will make the reporting of side-effect problems easier. Because of the limited populations involved in prelaunch trials, it is impossible to pick up every problem before a drug hits the market. So pharma companies must be diligent about minimizing the impact of adverse drug reactions. If the threat of being named and shamed is what it takes to make that happen, EMEA says, then so be it.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.